Previous 10 | Next 10 |
TD-0903, an inhaled pan-JAK inhibitor being developed by Theravance Biopharma ([[TBPH]] -3.4%) has demonstrated a favorable impact in hospitalized patients with severe COVID-19, according to data from a Phase 2 trial.The findings published in a pre-print pending a peer-review indica...
SVB Leerink has issued an outperform rating for Theravance Biopharma ([[TBPH]] +6.9%) citing that the market has attributed only ~$3 for its pipeline.With the price target at $41.00 per share implying ~112.3% upside to the previous close, the shares are trading higher in the morning hours tod...
Theravance Biopharma to Participate in an Upcoming Investor Conference PR Newswire DUBLIN , March 2, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and c...
The following slide deck was published by Theravance Biopharma, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Theravance Biopharma, Inc. 2020 Q4 - Results - Earnings Call Presentation
Image source: The Motley Fool. Theravance Biopharma Inc (NASDAQ: TBPH) Q4 2020 Earnings Call Feb 23, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Theravance Biopharma Inc (TBPH) Q4 2020 Earnings Call Transcript ...
Theravance Biopharma, Inc. (TBPH) Q4 2020 Earnings Conference Call February 23, 2021, 05:00 PM ET Company Participants Gail Cohen - VP, Corporate Communications and IR Rick Winningham - CEO Frank Pasqualone - Chief Commercial Operations Officer Brett Haumann - Chief Medical Officer Andrew Hin...
Theravance Biopharma (TBPH): Q4 GAAP EPS of -$0.92 beats by $0.10.Revenue of $18.73M (-36.5% Y/Y) misses by $2.11M.Cash, cash equivalents and marketable securities totaled $292.9 million as of December 31, 2020.2021 Financial Guidance: Operating Expenses (excluding share-based compensati...
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update - Company's implied 35% share of YUPELRI® (revefenacin) net sales¹: $13.6M Q4 2020, $50.0M FY 2020 - TD-0903: Company reports positive top-line resul...
Seth Klarman’s 13F portfolio value increased from $9.25B to $10.84B this quarter. Baupost Group added Intel, Marathon Petroleum, and a slew of SPACs during the quarter. The portfolio continues to be heavily concentrated with the top three positions accounting for ~36% of th...
Theravance Biopharma to Participate in Upcoming Investor Conferences PR Newswire DUBLIN , Feb. 10, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and com...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...